Sulfone metabolite of sulindac inhibits mammary carcinogenesis

Cancer Research

Volumn 57, Issue 2, 1997, Pages 267-271

  Thompson, Henry J ^a   Jiang, Cheng ^a   Lu, Junxuan ^a   Mehta, Rajendra G ^c   Piazza, Gary A ^b   Paranka, Nancy S ^b   Pamukcu, Rifat ^b   Ahnen, Dennis J ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b Cell Pathways Inc   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CARCINOGEN; DRUG METABOLITE; METHYLNITROSOUREA; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; FEMALE; GENE MUTATION; NONHUMAN; ONCOGENE H RAS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, RAS; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; SULINDAC;

EID: 0031035593     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55: 1464-1472, 1995.
2. Pepin, P., Bouchard, L., Nicole, P., and Castonguay, A. Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis (Lond.), 13: 341-348, 1992.
3. Carter, C. A., Ip, M. M., and Ip, C. A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis (Lond.), 10: 1369-1374, 1989.
4. Duggan, D. E., Hooke, K. F., Risley, E. A., Shen, T. Y., and Arman, C. G. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther., 201: 8-13, 1977.
5. Shen, T. Y., Ham, E. A., Cirillo, V. J., and Zanetti, M. Prostaglandin synthetase inhibitors (H. J. Robinson and J. R. Vane [eds]) Raven Press, NY, 1974.
6. Thompson, H. J., Briggs, S., Paranka, N. S., Piazza, G. A., Brendel, K., Gross, P. H., Sperl, G. J., Pamukcu, R., and Ahnen, D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl. Cancer Inst., 87: 1259-1260, 1995.
7. Alberts, D. S., Hixson, L., Ahnen, D., Bogert, C., Einspahr, J., Paranka, N., Brendel, K., Gross, P. H., Pamukcu, R., and Burt, R. W. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J. Cell Biochem. Suppl., 22: 18-23, 1995.
8. Roberts, A. Effects of prostaglandins on the stomach and intestine. Prostaglandins, 6: 523-532, 1974.
9. Davies, N. M. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis. Colon Rectum, 38: 1311-1321, 1995.
10. Harris, R. E., Namboodiri, K. K., and Farrar, W. B. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology, 7: 203-205, 1996.
11. Singh, J., Kulkarni, N., Kelloff, G., and Reddy, B. S. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis (Lond.), 15: 1317-1323, 1994.
12. Barbacid, M. ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
13. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
14. Sukumar, A., Nolario, V., Martin-Zanca, D., and Barbacid, M. Induction of mammary carcinoma in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (Lond.), 306: 658-661, 1983.
15. Zarbl, H., Sukumar, S., Arthur, A. V., Martin-Zanca, D., and Barbacid, M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylreas during initiation of mammary carcinogenesis in rats. Nature (Lond.), 315: 382-385, 1985.
16. Kumar, R., Sukumar, S., and Barbacid, M. Activation of ras oncogenes preceding the onset of neoplasia. Science (Washington DC), 248: 1101-1104, 1990.
17. Zhang, R., Haag, J. D., and Gould, M. N. Reduction in the frequency of activated ras oncogenes in rat mammary carcinomas with increasing N-methyl-N-nitrosourea doses or increasing prolactin levels. Cancer Res., 50: 4286-4290, 1990.
18. Schneider, B. L., and Bowden, G. T. Selective pressures and ras activation in carcinogenesis. Mol. Carcinog., 6: 1-4, 1992.
19. Mehta, R. G., and Moon, R. C. Characterization of effective chemopreventive agents in vitro using an initiation-promotion protocol. Anticancer Res., 11: 593-597, 1991.
20. Kerr, J. F. R., Wyllie, A. H., and Currie, A. R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer, 26: 239-257, 1972.
21. Williams, G. T. Programmed cell death: apoptosis and oncogenesis. Cell, 65: 1097-1098, 1991.
22. Piazza, G. A., Kulchak-Rahm, A. L., Krutzsch, M., Sperl, G., Paranka, N. S., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., Pamukcu, R., and Ahnen, D. J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
23. Chen, C. Y., and Faller, D. V. Direction of p21 ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene, 11: 1487-1498, 1995.
24. Thompson, H. J., Strange, R., and Schedin, P. J. Apoptosis in the genesis and prevention of cancer. Cancer Epidemiology, Biomarkers & Prev., 1: 597-602, 1992.
25. Thompson, H. J., and Adlakha, H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res., 51: 3411-3415, 1991.
26. Thompson, H. J., Ronan, A. M., Ritacco, K. A., and Tagliaferro, A. R. Effect of type and amount of dietary fat on the enhancement of rat mammary tumorigenesis by exercise. Cancer Res., 49: 1904-1908, 1989.
27. Young, S., and Hallowes, R. C. Tumors of the mammary gland. In: V. S. Turusov (ed.), Pathology of Tumours in Laboratory Animals, Vol. 1, pp. 31-73. IARC Scientific Publication. Lyon, France, 1973.
28. Lu, J., Jiang, C., Fontaine, S., and Thompson, H. J. ras may mediate mammary cancer promotion by high fat. Nutr. Cancer. 23: 283-290, 1995.
29. Mehta, R. G., and Banerjee, M. R. Hormonal regulation of macro molecular biosynthesis during lobulo-alveolor development of mouse mammary gland in organ culture. Acta Endocrinol., 80: 501-511, 1975.
30. Mehta, R. G., Cerny, W. L., Mandigan, M. J., and Moon, R. C. Modification of mouse mammary gland organ culture. J. Tissue Cut. Methods, 8: 27-35, 1984.
31. Duke, R. C., and Cohen, J. J. Morphological and biochemical assays of apoptosis. In: J. E. Coligan and A. M. Kruisbeak (eds.), Current Protocols in Immunology, pp. 3.17.1-3.17.16. New York: John Wiley & Sons, 1992.
32. Sokal, R. R., and Rohlf, F. J. Biometry: The Principles and Practice of Statistics in Biological Research, pp. 150, 384. San Francisco, CA: W. H. Freeman and Co., 1969.
33. Peto, R. Guidelines on the analysis of tumor rates and death rates in experimental animals. Br. J. Cancer, 29: 101-105, 1974.
34. Clark, G. J., and Der, C. Aberrant function of the ras signal transaction pathway in human breast cancer. Breast Cancer Res. Treat., 35: 133-144, 1995.
35. Rioux, N., and Castonguay, A. Modulation of lung tumorigenesis and immune response by nonsteroidal anti-inflammatory drugs in A/J mice. Proc. Am. Assoc. Cancer Res., 37: 284, 1996.